Immunotherapy: Hiding in plain sight: Immune escape in the era of targeted T-cell-based immunotherapies

Nature Reviews Clinical Oncology

Volumn 14, Issue 6, 2017, Pages 333-334

  Daniyan, Anthony F ^a   Brentjens, Renier J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR;

ADOPTIVE CELLULAR THERAPY; ADOPTIVE IMMUNOTHERAPY; B LYMPHOCYTE; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; T LYMPHOCYTE; TUMOR ESCAPE; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; PROCEDURES; T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION;

HUMANS; IMMUNOTHERAPY, ADOPTIVE; MOLECULAR TARGETED THERAPY; NEOPLASMS; T-LYMPHOCYTE SUBSETS; TUMOR ESCAPE;

EID: 85017446141     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2017.49     Document Type: Short Survey

References (9)

1. Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375, 2255-2262 (2016).
2. Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282-1295 (2015).
3. Evans, A. G. et al. Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. Br. J. Haematol. 171, 205-209 (2015).
4. Gardner, R. et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127, 2406-2410 (2016).
5. Jacoby, E. et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat. Commun. 7, 12320 (2016).
6. Rayes, A., McMasters, R. L. & O'Brien, M. M. Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr. Blood Cancer 63, 1113-1115 (2016).
7. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01701674 (2016).
8. Cha, E. et al. Improved survival with T cell clonotype stability sfter anti-CTLA-4 treatment in cancer patients. Sci. Transl Med. 6, 238ra70 (2014).
9. Ruella, M. et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J. Clin. Invest. 126, 3814-3826 (2016).